New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
January 30, 2025 - The FDA announced the approval of Vertex’s Journavx (suzetrigine), for the treatment of moderate to severe acute pain in adults.
Download PDF
Return to publications
